Successful Collaboration and Workshop: NGS in the Modern Clinical Lab

Athens, Greece

Share

Successful Collaboration and Workshop: NGS in the Modern Clinical Lab
Successful Collaboration and Workshop: NGS in the Modern Clinical Lab

In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.

Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.

Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.

In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.

Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.

Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.

In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.

Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.

Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.

In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.

Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.

Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About VARELAS S.A. 

Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals,  VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.

About VARELAS S.A. 

Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals,  VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.

About VARELAS S.A. 

Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals,  VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.

About VARELAS S.A. 

Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals,  VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.

METAGENOMIC SEQUENCING

COLLABORATION

VARELAS S.A.

Share this article :

Share

More Events

Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024

Mar 18, 2024

Join MGI at Spatial Biology UK 2024

Discover Genomic Innovations with MGI at Spatial Biology UK 2024! Join us on March 18th-19th at booth 15 at Novotel London West. Don't miss out!

Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference

Jan 27, 2024

Join us at EACR-AACR-IACR Basic and Translational Research Conference

Join us at booth 5 during the EACR-AACR-IACR Basic and Translational Research Conference with the MGI Team in Dublin, Ireland from February 27-29.

Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January

Jan 24, 2024

Join us at The Festival of Genomics & Biodata in January

Join us at booth 98 with MGI Tech during The Festival of Genomics & Biodata on January 24th-25th, 2024, at ExCeL in London.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.